Research and Development
Eurofins LifeCodexx – NIPT pioneer since 2010
Since 2010 we have been developing clinically validated, non-invasive genetic tests. Two years later, we launched PrenaTest®, the first non-invasive prenatal test (NIPT) in Europe. At that time it could determine trisomy 21, which leads to the Down syndrome. Now the PrenaTest® is able examine the complete set of chromosomes for possible changes. Of course, we will also endeavor to remain at the forefront of this field well into the future.
PrenaTest® now available for the detection of rare autosomal aneuploidy (rare autosomal aneuploidy, RAA). These are monosomies of chromosomes 13, 18 and 21 as well as monosomies and trisomies of chromosomes 1-12, 14-17, 19, 20 and 22.
Market launch of the PraenaRhD – Non-invasive prenatal RhD genotyping from maternal blood
5 years PrenaTest® – More than 80,000 successfully performed PrenaTest® analyzes in Germany with blood samples of pregnant women from 50 countries in Europe, the Middle East and Asia
CE approval for qPCR-based NIPT solution for the detection of fetal trisomy 21 (qNIPT)
Prospective clinical follow-up study with over 2,200 patients: Confirmation of the excellent test quality of the PrenaTest®
PrenaTest® now also for the determination of the 22q11.2 microdeletion
Start of development of a qPCR-based NIPT assay (qNIPT) with the aim of further reducing the test price and waiting time to the test result
Start of the development of an innovative NIPT data analysis system (PrenaBoxx®).
PrenaTest® now also determines sex chromosomal aneuploidy (Turner, Triple X, Klinefelter and XYY syndrome)
PrenaTest® now also applicable to twin pregnancies
Reduction of the waiting time to the test result to one week by introducing the PrenaTest®express
PrenaTest® now ready for use after the ninth week of pregnancy has been completed(week 9+0 since LMP)
Introduction of the proprietary QuantYfeX® assay to measure the fetal fraction upon
sample receipt
PrenaTest® now also determines fetal trisomies 13 and 18
Market launch of the PrenaTest® – Europe’s first NIPT – for the determination of fetal trisomy 21 from gestational week 12+0 since LMP
CE Marking of proprietary bioinformatic analysis software (PrenaTest® DAP.plus) according to European IVD Directive
License agreement with Sequenom Inc. (USA) for the acquisition of rights of use of essential patents as a legal requirement for the conduct of non-invasive prenatal tests (NIPT) in Germany
Start of operative work on research and development of innovative and clinically validated non-invasive genetic tests